In morning trade, the ASX 300 healthcare stock is up 34% to $7.25. Investors have been scrambling to buy the company's shares ...

The Melbourne-based nuclear medicine company is expected to be a major player in the US radiopharmaceutical market.

Monadelphous has secured new contracts in the resources, energy, and infrastructure sectors valued at $400 million.

Mineral Resources is in only reasonable financial health. Comparatively high current debt levels in conjunction with low lithium prices are somewhat of a concern, though in keeping with Mineral ...

Australia-listed Guzman y Gomez said on Friday its first-half earnings nearly doubled on strong demand for its breakfast menu ...

Black Cat Syndicate (BC8), Canyon Resources (CAY), Corporate Travel Management (CTD), Develop Global (DVP), MA Financial (MAF ...

US property giant CoStar has made a $2.7 billion takeover bid for Australia’s second-biggest real estate platform in the ...

Telix Pharmaceuticals 1H25 NPAT up 860% to $49.9m, FY25 revenue guidance of $1.18-1.23bn vs. $1.02bn consensus, R&D ...

Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered ...

On February 20, 2025, CoStar informed Domain that it had acquired 16.9% of Domain’s ordinary shares at $4.20 per share. The implementation of CoStar’s proposal is conditional on CoStar entering into ...

Bell Potter has a buy rating and $27.75 price target on the ASX 200 growth share. This implies potential upside of 13% from ...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story ...